ChiCTR2600117250 版本V1.0 版本创建时间2026/01/21 15:49:29 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2600117250 

最近更新日期:

Date of Last Refreshed on:

2026-01-21 15:49:21 

注册时间:

Date of Registration:

2026-01-21 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

AI辅助视网膜影像联合心血管超声对心梗后患者预后及不良事件的预测价值研究

Public title:

AI-Assisted Retina Imaging Combined with Cardiovascular Ultrasound in Predicting Prognosis and Adverse Events in Post-Myocardial Infarction Patients: A Study on Predictive Value

注册题目简写:

English Acronym:

研究课题的正式科学名称:

AI辅助视网膜影像联合心血管超声对心梗后患者预后及不良事件的预测价值研究

Scientific title:

AI-Assisted Retina Imaging Combined with Cardiovascular Ultrasound in Predicting Prognosis and Adverse Events in Post-Myocardial Infarction Patients: A Study on Predictive Value

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

尹玥 

研究负责人:

尹玥 

Applicant:

Yue Yin 

Study leader:

Yue Yin 

申请注册联系人电话:

Applicant telephone:

+86 10 84206584

研究负责人电话:

Study leader's
telephone:

+86 10 84206584

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

78230426@qq.com

研究负责人电子邮件:

Study leader's E-mail:

78230426@qq.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

北京市朝阳区樱花园东街2号

研究负责人通讯地址:

北京市朝阳区樱花园东街2号

Applicant address:

No. 2, Yinghua East Street, Chaoyang District, Beijing

Study leader's address:

No. 2, Yinghua East Street, Chaoyang District, Beijing

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

中日友好医院

Applicant's institution:

China-Japan Friendship Hospital

研究负责人所在单位:

中日友好医院

Affiliation of the Leader:

China-Japan Friendship Hospital

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2025-KY-411

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

中日友好医院临床研究伦理委员会

Name of the ethic committee:

Clinical Research Ethics Committee of China-Japan Friendship Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2025-12-11 00:00:00

伦理委员会联系人:

闫旭

Contact Name of the ethic committee:

Xu Yan

伦理委员会联系地址:

北京市朝阳区樱花园东街2号

Contact Address of the ethic committee:

No. 2, Yinghua East Street, Chaoyang District, Beijing

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 10 84206250

伦理委员会联系人邮箱:

Contact email of the ethic committee:

zryyec@126.com

研究实施负责(组长)单位:

中日友好医院

Primary sponsor:

China-Japan Friendship Hospital

研究实施负责(组长)单位地址:

北京市朝阳区樱花园东街2号

Primary sponsor's address:

No. 2, Yinghua East Street, Chaoyang District, Beijing

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

北京市

市(区县):

Country:

China

Province:

Beijing

City:

单位(医院):

中日友好医院

具体地址:

北京市朝阳区樱花园东街2号

Institution
hospital:

China-Japan Friendship Hospital

Address:

No. 2, Yinghua East Street, Chaoyang District, Beijing

经费或物资来源:

2025年度中日友好医院高水平医院临床业务费专项项目

Source(s) of funding:

National High Level Hospital Clinical Research Funding

研究疾病:

心梗  

Target disease:

Heart attack

研究疾病代码:

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

连续入组 

Study design:

Sequential 

研究目的:

项目目的一:解析视网膜影像与心血管超声的协同预警价值,建立视网膜影像联合心血管超声的心梗后患者眼部及心血管不良事件预测体系; 研究目的二:初步构建针对心梗患者的无创预后风险预测工具,指导二级预防策略。  

Objectives of Study:

Objective 1: Analyze the synergistic early-warning value of retinal imaging and cardiovascular ultrasound, and establish a prediction system for ocular and cardiovascular adverse events in post-myocardial infarction patients based on the combination of retinal imaging and cardiovascular ultrasound; Objective 2: Initially construct a non-invasive prognostic risk prediction tool for myocardial infarction patients, so as to guide secondary prevention strategies.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1.年龄 18-80 岁(含 80 岁); 2.确诊心肌梗死; 3.签署知情同意书.

Inclusion criteria

1.Age: 18-80 years old (inclusive); 2.Diagnosis of myocardial infarction; 3.Sign the informed consent form.

排除标准:

1.妊娠或哺乳期女性; 2.参与其他可能干扰本研究结果的临床试验; 3.严重认知障碍或精神疾病; 4.既往心脏移植或左心室辅助装置植入史; 5.既往肝、肺、肾移植史; 6.青光眼、病理性近视、视网膜手术后及其他影响视网膜影像采集的眼部疾病; 7.合并活动性感染性疾病或全身炎症反应综合征; 8.免疫系统性疾病活动期或正在接受激素、生物治疗; 9.严重肝功能障碍(Child-Pugh C 级); 10.临床医师判定的各系统疾病终末期,且预期寿命小于1年; 11.严重的出血、凝血倾向; 12.研究团队共同讨论后判定 的不符合入组的其他情况.

Exclusion criteria:

1.Pregnant or lactating women; 2.Participate in other clinical trials that may interfere with the results of this study; 3.Severe cognitive impairment or mental illness; 4.Previous history of heart transplantation or left ventricular assist device implantation; 5.Previous history of liver, lung and kidney transplantation; 6.Glaucoma, pathological myopia, post-retinal surgery and other eye diseases that affect retinal image acquisition; 7.Combined with active infectious diseases or systemic inflammatory response syndrome; 8.Active stage of immune system diseases or currently undergoing hormone or biological therapy; 9.Severe liver dysfunction (Child-Pugh grade C); 10.The terminal stage of diseases in various systems as determined by clinicians, and the life expectancy is less than one year; 11.Severe bleeding and clotting tendency; 12.Other circumstances that do not meet the criteria for inclusion as determined by the research team after joint discussion.

研究实施时间:

Study execute time:

From 2025-09-01 00:00:00 To 2027-08-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2026-02-01 00:00:00 To 2026-12-01 00:00:00

干预措施:

Interventions:

组别:

模型训练组

样本量:

175

Group:

Experimental group

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

组别:

模型验证组

样本量:

75

Group:

Validation group

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

北京市 

市(区县):

 

Country:

China

Province:

Beijing

City:

单位(医院):

中日友好医院 

单位级别:

三级甲等 

Institution
hospital:

China-Japan Friendship Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

视网膜照相

指标类型:

主要指标

Outcome:

Retinal photography

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

颈动脉超声

指标类型:

主要指标

Outcome:

carotid artery ultrasound

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

光学相干断层扫描影像数据

指标类型:

主要指标

Outcome:

Optical Coherence Tomography Image Data

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

光学相干断层扫描血管造影影像数据

指标类型:

主要指标

Outcome:

Optical coherence tomography angiography imaging data

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

眼动脉超声(眼动脉流速;眼动脉流速血流阻力;视网膜 中央动脉流速;视网膜中央动脉流速血流阻力)

指标类型:

主要指标

Outcome:

Ophthalmic artery ultrasound (ophthalmic artery flow velocity; ophthalmic artery flow resistance; central retinal artery flow velocity; central retinal artery flow resistance)

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血糖、血脂、肝肾功能

指标类型:

次要指标

Outcome:

Blood sugar, blood lipid, hepatic and renal function

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

超声心动图指标

指标类型:

主要指标

Outcome:

Echocardiography indicators

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

None

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age years
最大 Max age years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

None

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

Blinding:

None

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

None

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

通过病例报告表采集入试者基线及随访信息,生成病例记录表(CRF),影像学信息均去标识化采集并保存再研究组手中

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

The baseline and follow-up information of the subjects was collected through the case report form, and the case record form (CRF) was generated. The imaging information was de-identified, collected and saved in the hands of the study group

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2026-01-21 15:49:21